Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
About this item
Full title
Author / Creator
Publisher
Dordrecht: Springer
Journal title
Language
English
Formats
Publication information
Publisher
Dordrecht: Springer
Subjects
More information
Scope and Contents
Contents
Bevacizumab (Avastin, Genentech) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in both physiological and pathological conditions. It has been recently approved by the US FDA as a first-line therapy for widespread metastatic colorectal cancer. This report is a detailed b...
Alternative Titles
Full title
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_67300238
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_67300238
Other Identifiers
ISSN
0969-6970
E-ISSN
1573-7209
DOI
10.1007/s10456-004-8272-2
